BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
19 11 2022
Historique:
received: 11 09 2021
accepted: 08 11 2022
entrez: 19 11 2022
pubmed: 20 11 2022
medline: 23 11 2022
Statut: epublish

Résumé

NRAS-mutated melanoma lacks a specific line of treatment. Metabolic reprogramming is considered a novel target to control cancer; however, NRAS-oncogene contribution to this cancer hallmark is mostly unknown. Here, we show that NRAS

Identifiants

pubmed: 36402789
doi: 10.1038/s41467-022-34907-0
pii: 10.1038/s41467-022-34907-0
pmc: PMC9675737
doi:

Substances chimiques

Proto-Oncogene Proteins B-raf EC 2.7.11.1
Sorafenib 9ZOQ3TZI87
Glucose IY9XDZ35W2
BRAF protein, human EC 2.7.11.1
PFKFB2 protein, human EC 2.7.1.105
Phosphofructokinase-2 EC 2.7.1.105
NRAS protein, human EC 3.6.1.-
Membrane Proteins 0
GTP Phosphohydrolases EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7113

Informations de copyright

© 2022. The Author(s).

Références

J Invest Dermatol. 2004 Feb;122(2):337-41
pubmed: 15009714
Signal Transduct Target Ther. 2017 Nov 24;2:17044
pubmed: 29263928
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Mol Cell. 2015 Aug 6;59(3):382-98
pubmed: 26190261
Cancer Res. 2006 Oct 1;66(19):9483-91
pubmed: 17018604
Genes Dev. 2011 Mar 1;25(5):460-70
pubmed: 21317241
Clin Cancer Res. 2014 May 1;20(9):2257-63
pubmed: 24610826
Proc Natl Acad Sci U S A. 2021 Apr 6;118(14):
pubmed: 33785595
Nat Rev Mol Cell Biol. 2001 Oct;2(10):769-76
pubmed: 11584304
J Transl Med. 2011 May 24;9:76
pubmed: 21609436
Mol Cell Biol. 2002 May;22(10):3237-46
pubmed: 11971957
Nat Cancer. 2021 Mar;2(3):271-283
pubmed: 33870211
Nature. 1984 Mar 1-7;308(5954):69-72
pubmed: 6700714
N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
Sci Rep. 2019 May 10;9(1):7217
pubmed: 31076580
Genomics Proteomics Bioinformatics. 2020 Feb;18(1):72-80
pubmed: 32200042
PLoS One. 2009;4(3):e4771
pubmed: 19274086
Mol Syst Biol. 2011 Aug 16;7:523
pubmed: 21847114
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Nat Genet. 2003 Jan;33(1):19-20
pubmed: 12447372
BMC Cancer. 2010 Jun 08;10:265
pubmed: 20529342
Nat Commun. 2017 Oct 13;8(1):922
pubmed: 29030545
J Biol Chem. 2002 Mar 8;277(10):7913-9
pubmed: 11756411
Cancer Discov. 2014 Apr;4(4):423-33
pubmed: 24469106
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Front Oncol. 2018 Sep 04;8:331
pubmed: 30234009
Cancer Res. 2014 Jul 1;74(13):3535-45
pubmed: 24812272
Nucleic Acids Res. 2016 Jul 8;44(W1):W147-53
pubmed: 27190236
Mol Metab. 2019 Feb;20:1-13
pubmed: 30553771
Science. 2009 Sep 18;325(5947):1555-9
pubmed: 19661383
Int J Cancer. 2010 Apr 1;126(7):1549-61
pubmed: 19810100
Curr Opin Clin Nutr Metab Care. 2001 Sep;4(5):411-8
pubmed: 11568503
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8788-93
pubmed: 20421486
Science. 1999 Nov 26;286(5445):1741-4
pubmed: 10576742
Oncogene. 2013 Jun 20;32(25):3009-18
pubmed: 23069660
J Biol Chem. 1997 Jul 11;272(28):17269-75
pubmed: 9211863
Cell Metab. 2021 Nov 2;33(11):2247-2259.e6
pubmed: 34731655
Cell Metab. 2012 Feb 8;15(2):157-70
pubmed: 22326218
Trends Biochem Sci. 2001 Jan;26(1):30-5
pubmed: 11165514
J Biol Chem. 1993 May 25;268(15):10888-94
pubmed: 8098705
Anal Chem. 2021 Jan 26;93(3):1242-1248
pubmed: 33369389
Exp Cell Res. 2013 Jul 15;319(12):1732-1743
pubmed: 23701950
Cancer Res. 2000 Nov 1;60(21):6201-7
pubmed: 11085546
J Neurosci. 2005 Mar 16;25(11):2838-52
pubmed: 15772344
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cancer Res. 2018 May 1;78(9):2191-2204
pubmed: 29440170
Biochem J. 2004 Aug 1;381(Pt 3):561-79
pubmed: 15170386
Adv Enzymol Relat Areas Mol Biol. 1987;59:315-95
pubmed: 3028056
Nature. 2013 Apr 4;496(7443):101-5
pubmed: 23535601
Sci Signal. 2011 Sep 13;4(190):ra58
pubmed: 21917714
Nature. 2016 Sep 15;537(7620):422-426
pubmed: 27580028
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Chem Biol. 2015 Nov 19;22(11):1470-1479
pubmed: 26548610
EMBO Rep. 2018 Feb;19(2):320-336
pubmed: 29263201
Cell. 2012 Apr 27;149(3):656-70
pubmed: 22541435
Nat Genet. 2015 Sep;47(9):996-1002
pubmed: 26214590
Int J Mol Sci. 2019 Dec 29;21(1):
pubmed: 31905745
Mol Cell. 2015 Aug 6;59(3):345-358
pubmed: 26145173
Cancer Cell. 2013 Mar 18;23(3):287-301
pubmed: 23416000

Auteurs

Kimberley McGrail (K)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.

Paula Granado-Martínez (P)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.

Rosaura Esteve-Puig (R)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
MAJ3 Capital S.L, Barcelona, 08018, Spain.

Sara García-Ortega (S)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.

Yuxin Ding (Y)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.

Sara Sánchez-Redondo (S)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Microenvironment & Metastasis Group, Molecular Oncology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Berta Ferrer (B)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Anatomy Pathology Department, Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.

Javier Hernandez-Losa (J)

Anatomy Pathology Department, Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.

Francesc Canals (F)

Proteomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, 08035, Spain.

Anna Manzano (A)

Department of Physiological Sciences, University of Barcelona, Bellvitge Biomedical Research Institute, Barcelona, Spain.

Aura Navarro-Sabaté (A)

Department of Physiological Sciences, University of Barcelona, Bellvitge Biomedical Research Institute, Barcelona, Spain.

Ramón Bartrons (R)

Department of Physiological Sciences, University of Barcelona, Bellvitge Biomedical Research Institute, Barcelona, Spain.

Oscar Yanes (O)

Universitat Rovira i Virgili, Department of Electronic Engineering, IISPV, Tarragona, Spain.
CIBER on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Mileidys Pérez-Alea (M)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Advance Biodesign, 69800, Saint-Priest, France.

Eva Muñoz-Couselo (E)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Clinical Oncology Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.

Vicenç Garcia-Patos (V)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Dermatology Department, Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.

Juan A Recio (JA)

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain. juan.recio@vhir.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH